Molecure (WAR:MOC) Other Long Term Assets: zł0.08 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:MOC Molecure SA WAR:MOC
29 GF Score
Price zł7.38
! 3 Warning Signs
View Full Analysis

What is Molecure Other Long Term Assets?

Molecure WAR:MOC +2.50% 29 Other Long Term Assets is zł0.08 Mil as of Sep. 2025. GuruFocus rates WAR:MOC with a GF Score™ of 29/100. The stock has 3 warning signs investors should review.

Molecure's other long-term assets for the quarter that ended in Sep. 2025 was zł0.08 Mil.

Molecure's quarterly other long-term assets increased from Mar. 2025 (zł0.00 Mil) to Jun. 2025 (zł0.00 Mil) and increased from Jun. 2025 (zł0.00 Mil) to Sep. 2025 (zł0.08 Mil).

Molecure's annual other long-term assets declined from Dec. 2022 (zł0.00 Mil) to Dec. 2023 (zł0.00 Mil) but then stayed the same from Dec. 2023 (zł0.00 Mil) to Dec. 2024 (zł0.00 Mil).

Molecure Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Molecure's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecure Other Long Term Assets Chart

Molecure Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 0.00

Molecure Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.08
WAR:MOC
29GF Score
Molecure SA WAR:MOC
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecure Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of zł0.08 Mil mean?
Molecure (WAR:MOC) has a Other Long Term Assets of zł0.08 Mil as of Sep. 2025. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Molecure and its competitors.
Is Molecure's Other Long Term Assets too high?
Molecure's current Other Long Term Assets is zł0.08 Mil. Overall, Molecure has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Molecure's Other Long Term Assets compare to VRTX and REGN?
Molecure's Other Long Term Assets of zł0.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Molecure and its competitors. Molecure's current Other Long Term Assets is zł0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecure stock overvalued right now?
Molecure (WAR:MOC) has a current Other Long Term Assets of zł0.08 Mil. The current Other Long Term Assets is zł0.08 Mil. Molecure's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Molecure (WAR:MOC), the current Other Long Term Assets is zł0.08 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Molecure Business Description

Other Exchanges 1B1:Germany
Address Zwirki i Wigury 101, Warsaw, POL, 02-089
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.
29GF Score

Get the complete analysis for WAR:MOC

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.38
Price